Clinical Trial Update: Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating lenvatinib plus pembrolizumab in immune checkpoint inhibitor–naïve patients with metastatic uveal melanoma. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveal Melanoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: Providence Health & Services | Conditions: Melanoma, Uveal | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-07-25